Farah Marc, Straus Sabrina, Wang Grace, Gaffey Ann, Malas Mahmoud
Center for Learning and Excellence in Vascular and Endovascular Research (CLEVER), Division of Vascular & Endovascular Surgery, Department of Surgery, UC San Diego (UCSD), San Diego, CA; Georgetown University School of Medicine, Washington, DC.
Center for Learning and Excellence in Vascular and Endovascular Research (CLEVER), Division of Vascular & Endovascular Surgery, Department of Surgery, UC San Diego (UCSD), San Diego, CA.
Ann Vasc Surg. 2025 Nov;120:18-26. doi: 10.1016/j.avsg.2025.05.005. Epub 2025 May 9.
Smoking is known to be a strong predictive factor for deleterious outcomes after surgical procedures; however, there is limited research that has focused on the effect of smoking cessation on the outcomes of thoracic endovascular aortic repair (TEVAR). Using a multi-institutional database, we aimed to determine if smoking cessation was associated with improved outcomes following TEVAR.
Patients undergoing thoracic endovascular aortic repair in Vascular Quality Initiative from 2013 to 2023 were categorized into three groups: never smokers (NS), those who quit smoking (QS) >30 days prior, or current smokers (CS) who quit ≤30 days prior or never quit. Primary outcomes include perioperative death, stroke, myocardial infarction, and spinal cord ischemia. Secondary outcomes include cardiac and pulmonary complications, prolonged length of stay (≥2 days), and leg and bowel ischemia. A multivariate logistic regression analysis was conducted to control for confounding variables. A subanalysis was performed to determine the impact of smoking cessation by TEVAR indication: thoracic aortic aneurysm and type B aortic dissection. Long-term outcomes were analyzed using Kaplan-Meier and Cox regression models.
There were 1,435 (30.4%) patients in the NS group, 1,867 patients (39.6%) in the QS group, and 1,412 (30.0%) patients in the CS group. Patients in the QS group were older and had the highest rate of comorbidities including diabetes, myocardial infarction, and congestive heart failure. Multivariate analysis revealed that the CS group had no significant difference in odds of perioperative death (adjusted odds ratio (aOR) = 1.40; [95% confidence interval (CI): 0.86-2.25]; P = 0.2), stroke (aOR = 1.19; [95% CI: 0.71-1.99]; P = 0.5), myocardial infarction (aOR = 1.54; [95% CI: 0.74-3.17]; P = 0.2), and spinal cord ischemia (aOR = 1.52; [95% CI: 0.95-2.45]; P = 0.083) compared to QS. However, CS had increased odds of leg ischemia (aOR = 3.75; [95% CI: 1.79-8.25]; P < 0.001) and 1-year mortality (adjusted hazard ratio (aHR) = 1.34; [95% CI: 1.01-1.79] P = 0.042) compared to QS. When stratified by indication, thoracic aortic aneurysm CS compared to QS had higher rates of leg ischemia (aOR = 3.46; [95% CI: 1.28-10.1]; P = 0.017) and 3-year mortality (aHR = 1.44; [95% CI: 1.02-2.03]; P = 0.036). Type B aortic dissection CS had no significant difference in postoperative outcomes but showed increased odds of 1-year mortality (aHR = 2.51; [95% CI: 1.17-5.54]; P = 0.02) compared to QS.
CS had similar risk of death, stroke, myocardial infarction, and spinal cord ischemia when compared to QS, regardless of indication. However, there was a significantly increased risk of 1-year and 3-year mortality for CS which was not seen with QS when compared to NS. These results suggest surgery should not be delayed for smoking cessation; however, smoking cessation counseling may be important for improving long-term outcomes.
吸烟是手术预后不良的一个重要预测因素;然而,针对戒烟对胸主动脉腔内修复术(TEVAR)预后影响的研究有限。我们利用一个多机构数据库,旨在确定戒烟是否与TEVAR术后预后改善相关。
2013年至2023年参与血管质量倡议项目接受胸主动脉腔内修复术的患者被分为三组:从不吸烟者(NS)、戒烟超过30天者(QS)、戒烟≤30天或从未戒烟的当前吸烟者(CS)。主要结局包括围手术期死亡、中风、心肌梗死和脊髓缺血。次要结局包括心脏和肺部并发症、住院时间延长(≥2天)以及腿部和肠道缺血。进行多因素逻辑回归分析以控制混杂变量。进行亚组分析以确定按TEVAR适应证(胸主动脉瘤和B型主动脉夹层)划分的戒烟影响。使用Kaplan-Meier和Cox回归模型分析长期结局。
NS组有1435例患者(30.4%),QS组有1867例患者(39.6%),CS组有1412例患者(30.0%)。QS组患者年龄较大,合并症发生率最高,包括糖尿病、心肌梗死和充血性心力衰竭。多因素分析显示,与QS组相比,CS组在围手术期死亡几率(调整优势比(aOR)=1.40;[95%置信区间(CI):0.86 - 2.25];P = 0.2)、中风(aOR = 1.19;[95% CI:0.71 - 1.99];P = 0.5)、心肌梗死(aOR = 1.54;[95% CI:0.74 - 3.17];P = 0.2)和脊髓缺血(aOR = 1.52;[95% CI:0.95 - 2.45];P = 0.083)方面无显著差异。然而,与QS组相比,CS组腿部缺血几率增加(aOR = 3.75;[95% CI:1.79 - 8.25];P < 0.001),1年死亡率增加(调整风险比(aHR)= 1.34;[95% CI:1.01 - 1.79];P = 0.042)。按适应证分层时,与QS组相比,胸主动脉瘤CS组腿部缺血发生率更高(aOR = 3.46;[95% CI:1.28 - 10.1];P = 0.017),3年死亡率更高(aHR = 1.44;[95% CI:1.02 - 2.03];P = 0.036)。B型主动脉夹层CS组术后结局无显著差异,但与QS组相比,1年死亡率几率增加(aHR = 2.51;[95% CI:1.17 - 5.54];P = 0.02)。
无论适应证如何,CS组与QS组相比,在死亡、中风、心肌梗死和脊髓缺血风险方面相似。然而,与NS组相比,CS组1年和3年死亡率风险显著增加,而QS组未出现这种情况。这些结果表明,不应因戒烟而延迟手术;然而,戒烟咨询可能对改善长期结局很重要。